Download FREE Sample
Veterinary vaccines are biological preparations developed to prevent, control, or reduce the severity of infectious diseases in animals. These vaccines stimulate immune responses in livestock, companion animals, and, to a lesser extent, aquatic species. These products are essential not only for protecting companion animals and livestock but also for preventing the transmission of zoonotic diseases to humans, enhancing animal welfare, and reducing reliance on antibiotics. Some vaccine types include live attenuated, inactivated, recombinant, and toxoid vaccines, administered via injectable, oral, or intranasal routes. Veterinary vaccines play a central role in animal health management by supporting disease prevention strategies, safeguarding food-producing animals, and reducing the risk of zoonotic disease transmission to humans, among other benefits.
Disease prevention in livestock as a core growth driver
The increasing prevalence of zoonotic diseases and the growing reliance on veterinary vaccines to manage infectious diseases in livestock populations are some of the significant factors driving growth in the veterinary vaccines market. According to a National Institutes of Health (NIH) article, approximately 60% of emerging human pathogens and around 75% of all emerging infectious diseases are zoonotic. These figures highlight the significance of underscoring the link between human activity, such as land-use change, and zoonotic disease transmission. For instance, intensive farming practices and increased animal density elevate the risk of disease outbreaks, which result in substantial economic impacts, including reduced productivity, trade restrictions, and mortality. Consequently, vaccination programs are widely adopted as a cost-effective measure to maintain herd health and stabilize output in poultry, swine, cattle, and small ruminants. Government-supported immunization initiatives and biosecurity programs have reinforced vaccine adoption, particularly for diseases with cross-border or zoonotic implications. As protein consumption continues to rise globally, maintaining animal health through preventive immunization remains a structural requirement in sustainable livestock production systems, directly supporting sustained demand for veterinary vaccines.
Early detection and management are crucial to prevent outbreaks like avian influenza and rabies, which pose significant public health risks. This awareness has spurred investments in veterinary vaccines and healthcare infrastructure, particularly in regions vulnerable to diseases. By enabling precise monitoring and early intervention, these preventive measures are critical for mitigating potential pandemics and ensuring the health of both animals and humans.
To learn more about this report, download the PDF brochure
Expanding companion animal population supporting preventive vaccination
The rising global trend of pet ownership has increased the baseline demand for veterinary care and routine preventive interventions, including immunization. Pets are increasingly integrated into households, leading to greater investment in their health and well-being. Numerous studies highlight the positive health impacts of having a companion animal on humans and improving their overall well-being. The worldwide companion animal population has experienced substantial growth in recent years. This is evident in increasing pet ownership in the US over the last thirty years, with 66% of American households (equivalent to 86.9 million homes) owning a pet as of 2024, a rise from 56% reported in 1988, according to pet ownership data. (Source: APPA). This expanding animal base supports sustained demand for core and booster vaccinations s companion animal species.
This evolving dynamic highlights the growing societal commitment to animal welfare and underscores the critical role of advanced vaccines and immunization in ensuring high-quality veterinary care. As the demand for early detection and effective disease management continues to rise, veterinary vaccines remain integral in meeting the health needs of companion animals, driving the market's sustained growth and innovation.
Rising companion animal healthcare expenditure supporting vaccine uptake
Increasing healthcare expenditure per companion animal represents a significant opportunity for market players, driving substantial investment in preventive veterinary services. Rising pet ownership, urbanization, and growing animal welfare campaigns/programs have led to higher spending on preventive veterinary services, including routine immunization, as the owners increasingly view vaccinations as part of standard healthcare rather than optional interventions.
The vaccines demand is primarily influenced by the surge in companion-animal healthcare spending, along with pet owners increasing interest in more advanced therapies (biologics, oncology, and specialty medicines). In the US alone, total expenditure on pets (i.e., pet industry) increased substantially by c.46% between 2020-2024 while expenditure on pet health & products increased c.25% between 2020-2024 (Source: APPA).
Further, with a higher willingness to pay for comprehensive care, there is increasing demand for booster shots and broader vaccine coverage, making it an attractive area for product innovation and portfolio expansion. This trend is particularly evident in urban markets, where access to veterinary clinics and diagnostic services is expanding, allowing for higher vaccine compliance.
To learn more about this report, download the PDF brochure
Animal Type Segment Outlook
The veterinary vaccines market, based on animal type, is primarily segmented into livestock animals and companion animals. The subsegment livestock animals accounts for the largest share of the market, primarily due to the rising demand for routine immunization programs in poultry, cattle, and swine, among others, aimed at preventing infectious diseases and maintaining productivity. Furthermore, increasing commercialization of animal farming and the rising demand for protein-rich food, stricter government and regulatory requirements for prevention of diseases that affect the food supply (e.g., avian flu), and zoonotic disease control support consistent vaccine usage and the continued growth in this segment.
Companion animals, including dogs, cats, and horses, represent a comparatively smaller but fastest-growing segment in the market. The segment growth is driven byng pet adoption, increasing expenditure on preventive veterinary care, and greater awareness of vaccination as part of routine animal health management. Although the livestock segment represents the major market share, the increasing humanization of pets fuels rapid expansion in the companion animal sector.
Regional Outlook: North America is expected to hold a major share of the veterinary vaccines market
North America dominates the veterinary vaccines market, supported by established veterinary infrastructure, rising pet adoption and humanization, high awareness of preventive animal care, and strong regulatory frameworks. Europe follows closely, with rising zoonotic disease prevalence, which is driving the demand for animal vaccines across the region. Further, strong emphasis on food safety and government-led initiatives promoting vaccination to reduce disease outbreaks, especially in the livestock population, further support market growth in Europe. However, the Asia-Pacific region is expected to grow faster, driven by expanding livestock production, rising demand for animal protein, increasing pet ownership, growing awareness of zoonotic diseases, and increasing government initiatives in animal health management.
Competitive Landscape Analysis
The global veterinary vaccines market is marked by the presence of established and emerging market players such Zoetis (US); Merck & Co., Inc. (US); Boehringer Ingelheim Animal Health (Germany); Elanco Animal Health Incorporated (US); Virbac S.A. (France); Phibro Animal Health Corporation (US); Calier (Spain); Ceva (France); Bimeda Biologicals (US); Neogen Corporation (US) among others. Some of the key strategies adopted by market players include product innovation and development, strategic partnerships and collaborations, mergers and acquisitions, and geographic expansion.
Get a sample report for competitive landscape analysis
Report Scope
|
Report Metric |
Details |
|
Base Year Considered |
2025 |
|
Historical Data |
2024 2025 |
|
2026 2031 |
|
|
7% |
|
|
Segment Scope |
Animal Type, Product, Route of Administration, and End User |
|
Regional Scope |
|
|
Market Drivers |
|
|
Attractive Opportunities |
|
|
Key Companies Mapped |
Zoetis (US); Merck & Co., Inc. (US); Boehringer Ingelheim Animal Health (Germany); Elanco Animal Health Incorporated (US); Virbac S.A. (France); Phibro Animal Health Corporation (US); Calier (Spain); Ceva (France); Bimeda Biologicals (US); and Neogen Corporation (US), among others |
|
Report Highlights |
Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Veterinary Vaccines Market Segmentation
This report by Medi-Tech Insights provides thesize of the global veterinary vaccines market at theregional- and country-level from 2024 to 2031. The report further segments the market based on animal type, product, route of administration, and end user.
Market Size & Forecast (2024-2031), By Animal Type, USD Billion
- Livestock
- Cattle
- Poultry
- Swine
- Others
- Companion
- Canine
- Feline
- Others
Market Size & Forecast (2024-2031), By Product, USD Billion
- Attenuated Live Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
- Subunit Vaccines
Market Size & Forecast (20ute of Administration, USD Billion
- Subcutaneous
- Oral
- Intramuscular
- Intranasal
- Others
Market Size & Forecast (2024-2031), By End User, USD Billion
- Veterinary Hospitals
- Veterinary Clinics
- Others
Market Size & Forecast (2024-2031), By Region, USD Billion
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Related Reports
Need a More Tailored Analysis?
- Discuss the market sizing methodology and forecast assumptions with our healthcare analysts.
- Expand the scope with additional countries, market segments, technologies, or competitor profiling.
- Use the insights to support strategic planning, market entry, commercial due diligence, and long-term revenue growth initiatives.
